Browse by author
Lookup NU author(s): Professor Mark Thomason,
Dr Sarah Kelly
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The McGill consensus statement on overdentures (14) was published following a symposium held at McGill University in Montreal, Canada in 2002. A panel of relevant experts in the field stated that: The evidence currently available suggests that the restoration of the edentulous mandible with a conventional denture is no longer the most appropriate first choice prosthodontic treatment. There is now overwhelming evidence that a two-implant overdenture should become the first choice of treatment for the edentulous mandible (14). In 2009, a further consensus statement was released as a support and follow-up to the McGill consensus statement. This report was jointly created by members of the BSSPD (British Society for the Study of Prosthetic Dentistry) Council and the panel of presenters at the BSSPD conference in York, UK in April 2009 (15). This report also highlighted that since the McGill statement in 2002, uptake by dentists of implant technology for complete denture wearers has been slow. The York statement concluded that 'a substantial body of evidence is now available demonstrating that patients' satisfaction and quality of life with ISOD mandibular overdentures is significantly greater than for conventional dentures. Much of this data comes from randomised controlled trials (15). Whilst it is accepted that the two-implant overdenture is not the gold standard of implant therapy it is the minimum standard that should be sufficient for most people, taking into account performance, patient satisfaction, cost and clinical time. (C) 2011 Elsevier Ltd. All rights reserved.
Author(s): Thomason JM; Kelly SAM; Bendkowski A; Ellis JS
Publication type: Review
Publication status: Published
Journal: Journal of Dentisry
Print publication date: 03/09/2011
ISSN (print): 0300-5712
ISSN (electronic): 1879-176X
Publisher: ELSEVIER SCI LTD
PubMed id: 21911034